公开(公告)号：EP2717918A4

公开(公告)日：2015-03-18

申请号：EP12792243

申请日：2012-06-01

申请人： HANMI SCIENCE CO LTD

发明人： WOO YOUNG EUN ,  JANG MYUNG HYUN ,  PARK YOUNG JIN ,  PARK YOUNG KYUNG ,  LIM CHANG KI ,  KWON SE CHANG

IPC分类号： A61K47/48 ,  A61K38/28 ,  A61K47/30 ,  A61P3/10

CPC分类号： A61K47/48415 ,  A61K38/26 ,  A61K38/28 ,  A61K47/68 ,  A61K47/6811 ,  A61K47/6883

公开(公告)号：EP2718318A4

公开(公告)日：2014-12-31

申请号：EP12797363

申请日：2012-06-07

申请人： HANMI SCIENCE CO LTD

发明人： JUNG SUNG YOUB ,  JANG MYUNG HYUN ,  SHEN LING AI ,  PARK YOUNG KYUNG ,  PARK YOUNG JIN ,  KWON SE CHANG

IPC分类号： C07K14/605 ,  A61K38/26 ,  A61P3/04

CPC分类号： C07K14/605 ,  A61K38/00 ,  A61K38/177 ,  A61K38/22 ,  A61K38/26 ,  A61K45/06 ,  C07K14/575 ,  C07K14/705

摘要： The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

公开(公告)号：EP2537861B1

公开(公告)日：2014-11-26

申请号：EP12185376.6

申请日：2008-07-16

申请人： Hanmi Science Co., Ltd.

发明人： Kim, Young Hoon ,  Jung, Sung Youb ,  Kwon, Se Chang ,  Bae, Sung Min ,  Lee, Gwan Sun ,  Song, Dae Hae ,  Lim, Chang Ki

IPC分类号： C07K14/65 ,  C07K14/00

CPC分类号： C07K14/46 ,  A61K38/26 ,  C07K14/57563 ,  C07K14/605

公开(公告)号：EP2391365B1

公开(公告)日：2014-11-26

申请号：EP09838934.9

申请日：2009-12-28

申请人： Hanmi Science Co., Ltd.

发明人： WOO, Jong Soo ,  PARK, Jae Hyun ,  KIM, Yong Il ,  KIM, Kyeong Soo ,  YIM, Ho Taek ,  IM, Ji Hyun

IPC分类号： A61K31/44 ,  A61P9/10 ,  A61P9/00 ,  A61K31/4178

CPC分类号： A61K31/41 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2077 ,  A61K9/5084 ,  A61K31/4178 ,  A61K31/44 ,  A61K31/4422 ,  A61K2300/00

摘要： The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine and losartan as active ingredients, and a disintegrant which is a mixture of at least two components selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, and crosspovidone, which exhibits a high and stable level of amlodipine and losartan dissolution rates.

公开(公告)号：EP2721062A4

公开(公告)日：2014-11-12

申请号：EP12801247

申请日：2012-06-15

申请人： HANMI SCIENCE CO LTD

发明人： JUNG SUNG YOUB ,  KIM DAE JIN ,  PARK SUNG HEE ,  WOO YOUNG EUN ,  CHOI IN YOUNG ,  KWON SE CHANG

IPC分类号： C07K14/575 ,  A61K38/26 ,  A61K45/06 ,  A61K47/48 ,  A61P3/04 ,  C07K17/00

CPC分类号： A61K47/6889 ,  A61K38/00 ,  A61K38/26 ,  A61K45/06 ,  A61K47/48215 ,  A61K47/48369 ,  A61K47/48415 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6801 ,  A61K47/6811 ,  C07K14/575 ,  C07K2319/30

摘要： The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

摘要翻译： 本发明涉及包含胃泌酸调节蛋白，免疫球蛋白Fc区和非肽基聚合物的缀合物，其中通过非肽基聚合物共价连接胃泌酸调节蛋白与免疫球蛋白Fc区域可获得的缀合物和用于预防或治疗肥胖症的药物组合物 包括缀合物。 与天然胃泌酸调节蛋白不同，包含胃泌酸调节素和本发明的免疫球蛋白Fc的缀合物与天然胃泌酸调节素相比减少食物摄入，抑制胃排空，并且促进无副作用的脂肪分解，并且与天然胃泌酸调节素相比也显示出优异的受体激活作用和长期可持续性 。 因此，可广泛用于治疗肥胖症的安全性和有效性。

公开(公告)号：EP2037917B1

公开(公告)日：2014-10-08

申请号：EP07851323.1

申请日：2007-12-07

申请人： Hanmi Science Co., Ltd.

发明人： WOO, Jong Soo ,  YI, Hong Gi ,  CHI, Moon Hyuk ,  KIM, Kyeong Soo

IPC分类号： A61K31/44 ,  A61K45/06 ,  A61K31/4178 ,  A61K31/4422 ,  A61P9/00 ,  A61P9/10 ,  A61P9/04

CPC分类号： A61K31/44 ,  A61K9/2077 ,  A61K9/209 ,  A61K31/4178 ,  A61K31/4422 ,  A61K2300/00

摘要： Disclosed herein is a pharmaceutical composition comprising a part containing amlodipine or a pharmaceutically acceptable salt thereof and another separate part containing losartan or a pharmaceutically acceptable salt thereof, which exhibits improved preventive and therapeutic effects against cardiovascular disorders.

公开(公告)号：EP2717918A2

公开(公告)日：2014-04-16

申请号：EP12792243.3

申请日：2012-06-01

申请人： Hanmi Science Co., Ltd.

发明人： WOO, Young Eun ,  JANG, Myung Hyun ,  PARK, Young Jin ,  PARK, Young Kyung ,  LIM, Chang Ki ,  KWON, Se Chang

IPC分类号： A61K47/48 ,  A61K38/28 ,  A61K47/30 ,  A61P3/10

CPC分类号： A61K47/48415 ,  A61K38/26 ,  A61K38/28 ,  A61K47/68 ,  A61K47/6811 ,  A61K47/6883

摘要： The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved
in-vivo duration of efficacy and stability.

公开(公告)号：EP2542223A4

公开(公告)日：2014-01-15

申请号：EP11750883

申请日：2011-02-25

申请人： HANMI SCIENCE CO LTD

发明人： WOO JONG SOO ,  PARK JAE HYUN ,  KIM YONG IL ,  KIM DONG HO ,  CHOI JUN YOUNG

IPC分类号： A61K9/16 ,  A61K9/14 ,  A61K9/48 ,  A61K31/166 ,  A61K31/4468 ,  A61K31/5375 ,  A61K35/74 ,  A61K47/34

CPC分类号： A61K31/00 ,  A61K9/4808 ,  A61K9/4891 ,  A61K31/166 ,  A61K31/4468 ,  A61K31/5375 ,  A61K35/74

公开(公告)号：EP2558077A4

公开(公告)日：2014-01-01

申请号：EP11769045

申请日：2011-04-12

申请人： HANMI SCIENCE CO LTD

发明人： JANG KI YOUNG ,  PARK MIJIN ,  KIM KYEONG SOO ,  KIM YONG IL ,  PARK JAE HYUN ,  WOO JONG SOO

IPC分类号： A61K9/22 ,  A61K9/16 ,  A61K31/192

CPC分类号： A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K31/192

公开(公告)号：EP1831236A4

公开(公告)日：2013-11-20

申请号：EP05823850

申请日：2005-12-29

申请人： HANMI SCIENCE CO LTD

发明人： LEE JAEHEON ,  PARK GHA SEUNG ,  LEE MOONSUB ,  BANG HYO-JEONG ,  LEE JAE CHUL ,  KIM CHEOL KYONG ,  CHOI CHANG-JU ,  KIM HAN KYONG ,  LEE HOE CHUL ,  CHANG YOUNG-KIL ,  LEE GWAN SUN

IPC分类号： C07H19/04

CPC分类号： C07H19/04

摘要： This invention relates to an improved method for stereoselectively preparing 2¢¥-deoxy-2¢¥,2¢¥-difluorocytidine of formula (I), which comprises the steps of reacting a 1-halo ribofuranose compound of formula (III) with a nucleobase of formula (IV) in a solvent to obtain a nucleoside of formula (II) with removing the silyl halide of formula (V) produced during the reaction; and deprotecting the nucleoside of formula (II) to obtain 2¢¥-deoxy-2¢¥,2¢¥-difluorocytidine of formula (I).

摘要翻译： 本发明涉及立体选择性地制备式（I）的2β-脱氧-2β，2β-二氟胞苷的改进方法，该方法包括使式（III）的1-卤代呋喃核糖化合物与式 （IV）的核碱在溶剂中反应以获得式（II）的核苷，同时除去在反应期间产生的式（V）的甲硅烷基卤化物; （II）的核苷去保护，得到式（I）的2' - 脱氧-2'，2'' - 二氟胞苷。